Xoft Inc. recently received FDA clearance for applicators to be used with the Axxent Electronic Brachytherapy System for the treatment of endometrial cancer.
Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, also recently received expanded FDA clearance for use in the treatment of other cancers or conditions where radiation therapy is indicated.
February 12, 2024 
